AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sprouty-related, EVH1 domain-containing protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q7Z699

UPID:

SPRE1_HUMAN

Alternative names:

-

Alternative UPACC:

Q7Z699; B2RPJ8; Q05D53; Q8N256

Background:

Sprouty-related, EVH1 domain-containing protein 1 plays a pivotal role in cellular processes by inhibiting growth-factor-mediated activation of MAP kinase and negatively regulating hematopoiesis of bone marrow. It also plays a role in inhibiting fibroblast growth factor-induced retinal lens fiber differentiation and attenuates actin stress fiber formation, highlighting its multifaceted role in biological systems.

Therapeutic significance:

Linked to Legius syndrome, a condition characterized by cafe-au-lait macules, macrocephaly, and learning disabilities, this protein's genetic variants offer a unique insight into disease mechanisms. Understanding the role of Sprouty-related, EVH1 domain-containing protein 1 could open doors to potential therapeutic strategies for managing Legius syndrome and related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.